Exscientia
Applying artificial intelligence and big data processing to accelerate discovery and development of drugs.
| GBP | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 10 % | 58 % | (1 %) | (3 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (73 %) | (240 %) | (207 %) | (697 %) | (717 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (69 %) | (230 %) | (180 %) | (436 %) | (727 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 73 % | 113 % | 161 % | 473 % | 640 % |
Source: Company filings or news article
Related Content
Exscientia is a technology-driven company specializing in the design and development of drugs using artificial intelligence (AI). The company operates in the pharmaceutical and biotechnology market, focusing on creating more effective medicines at a faster pace. Exscientia serves pharmaceutical companies, research institutions, and healthcare providers by leveraging AI to enhance drug discovery and development processes. The business model revolves around partnerships and collaborations with major pharmaceutical firms, where Exscientia provides its AI-driven solutions to accelerate drug development. Revenue is generated through milestone payments, licensing fees, and royalties from successfully developed drugs.
Keywords: AI, drug design, drug development, pharmaceutical, biotechnology, healthcare, partnerships, licensing, royalties, innovation.
Tech stack
Investments by Exscientia
Edit
